IL-17 and its role in psoriasis
References
Ariza ME, Williams MV, Wong HK. Targeting IL-17 in psoriasis: from cutaneous immunobiology to clinical application. Clin Immunol. 2013;146:131-9.
Raychaudhuri SP. Role of IL-17 in psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol. 2013;44:183-93.
Aggarwal S, Gurney AL. IL-17: prototype member of an emerging cytokine family. J Leukocyte Biol. 2002;71:1-8.
Johansen C, Usher PA, Kjellerup RB, Lundsgaard D, Iversen L, Kragballe K. Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br J Dermatol. 2009;160:319-24.
Mudigonda P, Mudigonda T, Feneran AN, Alamdari HS, Sandoval L, Feldman SR. interleukin-23 and interleukin-17: importance in pathogenesis and therapy of psoriasis. Dermatol Online J. 2012;18 (10):1.
Krueger JG, Fretzin S, Suárez-Fariñas M, Haslett PA, Phipps KM, Cameron GS et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol. 2012;130:145-54.
Martin DA, Towne JE, Kricorian G, Klekotka P, Gudjonsson JE, Krueger JG et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol. 2013;133:17-26.
Kawaguchi M, Adachi M, Oda N, Kokubu F, Huang SK. IL-17 cytokine family. J Allergy Clin Immunol. 2004;114:1265-73.
Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012;366(13): 1181–9.
Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, Braun D et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366:1190-9.
Papp KA, Langley RG, Sigurgeirsson B, Abe M, Baker DR, Konno P et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol. 2013;168:412-21.